When farm challenges grow, smart tools need to grow with them.
Updated
January 8, 2026 6:32 PM
A drone spraying water over an agricultural field. PHOTO: FREEPIK
Farms today are under pressure. Fields are getting bigger, workers are harder to find and many jobs still rely on long hours of manual labor. XAG’s new P150 Max agricultural drone is designed for exactly this reality. Instead of replacing farmers, it takes over the heavy, repetitive fieldwork that slows them down, making farm operations more efficient and more precise.
The P150 Max is built around one simple idea: a single machine that can handle multiple farming tasks. Most farm drones focus only on spraying or mapping, but this one is fully modular. With a quick switch of attachments, it can spray crops, spread seeds or fertilizer, map fields or transport supplies. This flexibility helps farmers keep up with changing tasks throughout the day without needing different machines, improving both productivity and cost-efficiency.
A key challenge in agriculture is that fields are rarely smooth or predictable. Tractors can get stuck, smaller drones can’t carry much and some areas—like orchards or hilly plots—are simply hard to reach. The P150 Max fills that gap with an 80-kilogram payload and fast flight speed, letting it cover more ground per trip. Fewer takeoffs mean less downtime and more work completed before weather or daylight cuts operations short.
When it’s time to spray, the drone uses a smart spraying system that allows farmers to adjust droplet size based on the crop’s needs. This matters because precise spraying reduces waste and improves targeting. With an output of up to 46 liters per minute, the drone can serve both large open fields and dense orchards where consistent coverage is traditionally difficult.
The spreading system applies the same logic. Instead of dropping seeds or fertilizer unevenly, the vertical mechanism spreads material smoothly and resists wind drift. This ensures uniform application across irregular or hard-to-reach land—an ongoing challenge for modern farms aiming for higher yield and better resource use.
Another everyday issue for farmers is understanding and surveying the land before working on it. The P150 Max helps here with a built-in mapping tool that covers up to 20 hectares per flight and instantly converts the images into detailed maps. With AI detecting obstacles like trees or irrigation lines, the drone can plan safe and efficient autonomous routes, reducing manual planning time.
Beyond spraying and spreading, the drone can transport tools, produce and farm supplies using a sling attachment. This is particularly helpful after heavy rain, when vehicles cannot easily move across muddy or flooded fields.
Under all these functions is XAG’s upgraded flight control system, which provides centimeter-level accuracy even when network signals are weak. Integrated sensors—including 4D radar and a wide-angle camera—help the drone recognize hazards such as poles and wires. Farmers can manage all operations through the XAG One app or a handheld controller, both of which automatically generate the best route based on field shape and terrain.
Since long field days require long operating hours, the fast-charging battery system can recharge in about seven minutes using a dedicated kit. This supports continuous drone use throughout the day with minimal interruptions.
After years of testing, the XAG P150 Max is essentially an effort to make practical, scalable farm automation more accessible. By combining spraying, spreading, mapping and transport into one heavy-duty platform, it offers a way to ease labor shortages while keeping operations efficient and sustainable. Instead of focusing on one task, the drone aims to take over the time-consuming physical work so farmers can focus on decisions, planning and crop management.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.